High-affinity calcium-binding site in the gama-carboxyglutamic acid domain of bovine factor VII.
The calcium-mediated interaction of factor VIIa with tissue factor is considered to be the primary trigger of blood coagulation. To determine the role of calcium ions in the action of factor VII, we prepared monoclonal antibodies whose binding to factor VII was calcium-dependent. A monoclonal antibody designated C6 strongly inhibited factor VII-induced clotting at a molar ratio of factor VII to antibody of 1:1. The half-maximal binding of factor VII to the C6 antibody was observed at a concentration of calcium ions of 80 microM. Proteolytic fragments of factor VII were assayed for their ability to inhibit competitively the binding of 125I-factor VII to immobilized C6 antibody. The binding was inhibited by increasing amounts of factor VII, by a fragment that contained the gamma-carboxyglutamic acid (Gla) domain linked to first epidermal growth factor-like domain, and by a Gla domain peptide (residues 1-41), over a range of concentration of 10(-9) to 10(-7) M. The antigenic site recognized by the monoclonal antibody C6, which was generated upon the high-affinity binding of calcium ions, was located in the Gla domain. The C6 antibody inhibited the activation of factor X and the amidolytic activity of factor VIIa in the presence of tissue factor. These results demonstrate that a high-affinity calcium-binding site(s) is located in the Gla domain of factor VII, which is concerned with the initiation of tissue factor-mediated blood coagulation by factor VIIa.
Inoue
K
K
Department of Biochemistry, Meiji College of Pharmacy, Yato-cho, Tanashi, Tokyo, Japan.
Shimada
H
H
Ueba
J
J
Enomoto
S
S
Tanaka-Saisaka
Y
Y
Kubota
T
T
Koyama
M
M
Morita
T
T
D015055:1-Carboxyglutamic Acid / Q000031:analogs & derivatives / Q000737:chemistry; D000596:Amino Acids / Q000032:analysis; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D001665:Binding Sites; D001667:Binding, Competitive; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology; D002417:Cattle; D004815:Epidermal Growth Factor / Q000737:chemistry; D000939:Epitopes / Q000737:chemistry; D005167:Factor VII / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism; D015942:Factor VIIa / Q000037:antagonists & inhibitors; D005170:Factor X / Q000037:antagonists & inhibitors; D007700:Kinetics; D010446:Peptide Fragments / Q000737:chemistry / Q000494:pharmacology; D011485:Protein Binding
D000596:Amino Acids; D000911:Antibodies, Monoclonal; D000939:Epitopes; D010446:Peptide Fragments; D015055:1-Carboxyglutamic Acid; D004815:Epidermal Growth Factor; D005167:Factor VII; D005170:Factor X; D015942:Factor VIIa; D002118:Calcium